Drug Information

Drug General Information
Drug ID
D0U7HL
Former ID
DCL000890
Drug Name
N-5984
Drug Type
Small molecular drug
Indication Obesity; Type 2 diabetes [ICD9: 250, 250.00, 250.02, 278; ICD10:E08-E13, E11, E66] Phase 2 [536122]
Company
Nisshin Kyorin
Structure
Download
2D MOL

3D MOL
Formula
C20H22ClNO5
Canonical SMILES
CC(CC1=CC2=C(C=C1)OC(CO2)C(=O)O)NCC(C3=CC(=CC=C3)Cl)O
InChI
1S/C20H22ClNO5/c1-12(22-10-16(23)14-3-2-4-15(21)9-14)7-13-5-6-17-18(8-13)26-11-19(27-17)20(24)25/h2-6,8-9,12,16,19,22-23H,7,10-11H2,1H3,(H,24,25)/t12-,16+,19-/m1/s1
InChIKey
XSOXUIXLUNBLJA-RNRVQEDPSA-N
PubChem Compound ID
9865284
PubChem Substance ID
14830019, 14854232, 24157342, 45287552, 79214594, 129734988, 134339343, 140812857, 223739809, 226696974
Target and Pathway
Target(s) Beta-3 adrenergic receptor Target Info Agonist [536122]
KEGG Pathway Calcium signaling pathway
cGMP-PKG signaling pathway
Neuroactive ligand-receptor interaction
Endocytosis
Salivary secretion
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Beta3 adrenergic receptor signaling pathway
Reactome Adrenoceptors
G alpha (s) signalling events
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 536122Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
Ref 536122Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.